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Abstract
The intracellular endosymbiotic bacteriumWolbachia can protect insects against viral infec-
tion, and is being introduced into mosquito populations in the wild to block the transmission of
arboviruses that infect humans and are a major public health concern. To investigate the
mechanisms underlying this antiviral protection, we have developed a newmodel system
combiningWolbachia-infectedDrosophila melanogaster cell culture with the model mosquito-
borne Semliki Forest virus (SFV; Togaviridae, Alphavirus).Wolbachia provides strong antiviral
protection rapidly after infection, suggesting that an early stage post-infection is being
blocked.Wolbachia does appear to havemajor effects on events distinct from entry, assem-
bly or exit as it inhibits the replication of an SFV replicon transfected into the cells. Further-
more, it causes a far greater reduction in the expression of proteins from the 3´ open reading
frame than the 5´ non-structural protein open reading frame, indicating that it is blocking the
replication of viral RNA. Further to this separation of the replicase proteins and viral RNA in
transreplication assays shows that uncoupling of viral RNA and replicase proteins does not
overcomeWolbachia’s antiviral activity. This further suggests that replicative processes are
disrupted, such as translation or replication, byWolbachia infection. This may occur byWol-
bachiamounting an active antiviral response, but the virus did not cause any transcriptional
response by the bacterium, suggesting that this is not the case. Host microRNAs (miRNAs)
have been implicated in protection, but again we found that host cell miRNA expression was
unaffected by the bacterium and neither do our findings suggest any involvement of the antivi-
ral siRNA pathway. We conclude thatWolbachiamay directly interfere with early events in
virus replication such as translation of incoming viral RNA or RNA transcription, and this likely
involves an intrinsic (as opposed to an induced) mechanism.
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Author Summary
The intracellular endosymbiotic bacteriumWolbachia can protect insects against viral
infection. However, the mechanisms underlying this antiviral activity are poorly under-
stood. We have developed a new model system combiningWolbachia-infected Drosophila
melanogaster cell culture and the model mosquito-borne virus, Semliki Forest virus.Wol-
bachia confers strong antiviral activity against SFV. Our study indicates that viral replica-
tion appears to be inhibited at a very early stage, such as initial translation or replication.
Results indicate thatWolbachia does not mount a transcriptional response to SFV infec-
tion and that host small RNA pathways are not involved inWolbachiamediated antiviral
activity in our system. We conclude thatWolbachiamay directly interfere with early
events in virus replication such as translation of incoming viral RNA or RNA transcrip-
tion, and this likely involves an intrinsic (as opposed to an induced) mechanism.
Introduction
Arthropod-borne viruses (arboviruses) pose a considerable threat to human and animal health,
yet effective control measures have proven difficult to implement [1, 2]. In recent years novel
means of reducing their replication in arthropod vectors have been suggested as an alternative
way to reduce the prevalence of these viruses. One of the most exciting approaches is the use of
the endosymbiotic intracellular bacteriumWolbachia to control arbovirus transmission from
mosquito to vertebrate from within the arthropod vector [3, 4].Wolbachia was first found to
confer resistance to viruses in Drosophila melanogaster [5, 6]. When it was transferred to the
mosquito Aedes aegypti it made the mosquitoes resistant to two important human pathogenic
arboviruses, dengue virus (DENV) and chikungunya virus (CHIKV) [7, 8]. Importantly,Wol-
bachia can also invade and be stably maintained in natural populations thanks to a trait called
cytoplasmic incompatibility, which causes embryos to die when uninfected females mate with
infected males [9]. This allowsWolbachia to spread through mosquito populations by provid-
ing a reproductive advantage to theWolbachia-infected females that transmit the bacterium
[10]. Field trials have shown that releasingWolbachia-infected mosquitoes allows the bacte-
rium to invade Ae. aegypti populations [11, 12] and reduces the susceptibility of the mosquitoes
to DENV [13].
The mechanism(s) by whichWolbachia confers broad resistance remains unclear. Antiviral
protection is seen in insects that harbour high densities ofWolbachia [14, 15]. For example
Martinez et al (2014) showed a clear correspondence betweenWolbachia density and the level
of protection against the insect viruses, Drosophila C virus (DCV) and Flock House virus
(FHV) [16]. This phenomenon is also seen in the mosquito Ae. albopictus, where the endoge-
nousWolbachia strains wAlbA and wAlbB have a relatively low density especially in key tissues
such as the midgut and offer little protection against DENV [17, 18]. It has also been hypothe-
sised thatWolbachia protection is dependent on target cells and tissues harbouringWolbachia
[8, 14, 17]. Indeed, there is little evidence ofWolbachia and virus being present together in the
same cell when either is present in a high density, suggesting that antiviral protection is cell
autonomous [8, 19]. It may be a case of competition for space or cellular resources [8]. Viruses
andWolbachia depend on host lipids, and in D.melanogaster it has been shown that enriching
dietary cholesterol reduced the extent to whichWolbachia protects against DCV [20]. It has
also been suggested that there is competition for iron resources within cells, asWolbachia upre-
gulates transferrin in mosquitoes while DENV and CHIKV are thought to cause its downregu-
lation [21, 22].
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Viral replication is controlled by innate immune responses in both D.melanogaster and
mosquitoes and several experiments suggested that the upregulation of immune pathways—
immune-priming—may be important forWolbachia-mediated antiviral activity [17, 23, 24].
However, this appears to only be the case in mosquito populations that have been transinfected
withWolbachia strains [21, 24]. Drosophila species that are naturally infected withWolbachia
do not show an immune-priming phenotype, yet still confer antiviral activity [6, 15, 21, 25].
RNAi is considered the most important antiviral response in insects, with double stranded
viral RNA (dsRNA) being processed into short RNAs by the small interfering RNA (siRNA)
pathway and directing the destruction of viral RNA [26, 27]. However, several studies have
shown thatWolbachia provides protection in mutant Drosophila and cells that lack compo-
nents of this pathway, ruling out a role for the siRNA pathway inWolbachia-mediated protec-
tion [19, 28, 29]. There is however data that suggest the miRNA pathway may play a role in
Wolbachiamediated protection [30–32].Wolbachia has been shown to alter the expression of
multiple miRNAs in mosquitoes [31]. The miRNA pathway is involved in many cellular pro-
cesses, and miRNAs are produced from genome-encoded nuclear precursor RNAs that are
processed into 22 nucleotide (nt) molecules that can induce target RNA degradation or inhibi-
tion of translation [26, 33].
In summary, the mechanism(s) by whichWolbachia confers antiviral activity are still
unclear, and very little is known about exactly how the viral replication cycle is affected. Fur-
thermore, it is not clear ifWolbachia itself responds to viral infection. In order to address these
questions and to understand howWolbachia interacts with viruses we have combined two
powerful and well-studied model systems–the mosquito-borne alphavirus Semliki Forest virus
(SFV; Togaviridae, genus Alphavirus) and aWolbachia-containing D.melanogaster cell line
[34]–and show that the endosymbiont provides strong protection against infection in this sys-
tem. To identify the stage of the viral replication cycle that is likely being affected we compared
SFV, SFV replicon and a SFV-based transreplicase system. We then used high-throughput
sequencing to unravel the role of host small RNA pathways and theWolbachia transcriptional
response in antiviral protection. We find thatWolbachia targets the virus rapidly after infec-
tion, and is likely blocking early events in the replication of viral RNA (for example translation
of incoming RNA, the switch from translation to replication or RNA transcription) within
cells, though we cannot rule out an effect on entry or exit. These effects are neither associated
with a host small RNA response nor a transcriptional response by the endosymbiont, but medi-
ated by intrinsic activities.
Results
Wolbachia has no effect on cell growth but significantly decreases SFV
replication in D.melanogaster Jw18 cells
We developed a model arbovirus infection system based on SFV, for which excellent molecular
tools including replicons and recombinant viruses are available and which we have used exten-
sively to study arbovirus-arthropod interactions [35–37], and the D.melanogaster-derived
Jw18 cell line infected with theWolbachia strain wMel [34].
As SFV does not naturally infect D.melanogaster, we first established if this virus is able to
infect and replicate in Jw18 cells. We used SFV4(3H)-RLuc, which expresses Renilla luciferase,
RLuc, from the non-structural open reading frame (Fig 1A) and has been used previously to
study antiviral mechanisms in mosquito cells [36, 37].
The cells were first antibiotic treated to generate aWolbachia-free control cell line, which
we refer to as Jw18Free cells. These were infected at a multiplicity of infection (MOI) of 20 and
cells were lysed 4, 8, 12 and 24 hours post infection (hpi) and RLuc activity measured. Over a
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24 hour period RLuc activity gradually increased, indicating that SFV4(3H)-RLuc can infect
and replicate in Jw18Free cells (Fig 2A). In order to rule out any effect ofWolbachia or SFV on
cell growth we next compared the growth of cells Jw18Free and Jw18Wol cells either infected
or not infected with SFV4(3H)-RLuc. There was no significant difference between any of the
treatments observed, indicating that neitherWolbachia nor SFV4(3H)-RLuc infection affected
cell growth (Fig 2B). It is important to note that SFV does not cause cytopathic effects in insect
cells and therefore cells are able to continue to grow even under high infection rates.
To determine ifWolbachia could protect against SFV infection in Jw18 cells, we infected
Jw18Wol and Jw18Free cells with SFV4(3H)-RLuc (infectivity>90%) and measured RLuc
Fig 1. Virus, replicon and transreplicase systems used in this study. (A) Schematic representation of genome of SFV4(3H)-RLuc, carrying the RLuc
reporter gene flanked by duplicated nsP2-protease cleavage sites at the nsP3/4 junction. Note that the genome is split into two major ORFs, 1 and 2,
encoding non-structural and structural proteins respectively. (B) Schematic representation of the genome of viral replicon pSFV1(3F)RLuc-SG-FFLuc, where
RLuc is fused to the region encoding for nsP3 and the structural genes have been replaced by the reporter gene firefly luciferase (FFLuc). Expression of
FFLuc occurs only from subgenomic RNA produced from the subgenomic promoter; hence detection of this marker is dependent on the active replication of
transfected RNA. (C-D) Schematic representation of the SFV-derived transreplicase constructs used in this study. Expression of the replicase proteins is
under the control of the Drosophila Actin promoter (C). Expression of SFV template RNA is also under the control of the Actin promoter (D). When the
replicase proteins are expressed this leads to active replication of the template RNA. FFLuc expression is therefore under both the control of the Actin
promoter and the SFV genomic promoter. WhereasGluc is exclusively under the control of the subgenomic promoter and therefore requires active
replication of the template RNA in order for expression to occur. Two replicase constructs were used in this study: one functional, and one non-functional due
to the insertion of a GDD-GAAmutation in nsP4 as indicated in (C).
doi:10.1371/journal.ppat.1005536.g001
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activity at 7 and 24 hpi as a proxy for viral replication and spread [38]. Results indicated that
even as early as 7 hpi inhibition of virus byWolbachia is observed, with a 2–3 fold increase in
RLuc activity in Jw18Free cells compared to Jw18Wol cells. By 24 hpi this difference is more
marked with an 8–12 fold increase in RLuc activity in the Jw18Free cells (Fig 2C). Therefore,
Wolbachia confers antiviral protection against an arbovirus in this system. Furthermore the
mechanism by whichWolbachia inhibits viral infection must be rapid suggesting either entry
of the virus is inhibited or replication/translation are inhibited.
Fig 2. Analysis of cell growth and infection dynamics of Jw18Wol and Jw18Free cells infected with SFV. (A) Jw18Free cells were infected with SFV
(3H)-RLuc at an MOI of 20. Cells were lysed 4, 8, 12 and 24 hpi and RLuc activity determined. The figure represents data from three independent
experiments, where each treatment was carried out in triplicate. (B) The density of Jw18Wol and Jw18Free cells 7 and 24 hpi with SFV(3H)-RLuc at an MOI
of 20; 0 (seed) is 24 h prior to infection. Data represents three independent experiments carried out in duplicate. (C) Jw18Wol and Jw18Free cells were
infected at an MOI of 20 with SFV4(3H)-RLuc and RLuc activity was measured at 7 and 24 hpi. The graph indicates the mean ratio of RLuc activity in
Jw18Wol and Jw18Free cells, where Jw18Wol at 7hpi and 24 hpi is equal to one. The data represents five independent experiments carried out in duplicate.
Error bars represent the standard error of mean in all figures. Stars indicate significance P = <0.05 in T-Test analysis.
doi:10.1371/journal.ppat.1005536.g002
Antiviral Protection byWolbachia
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Suppression of reporter gene expression mediated by activity of the viral
subgenomic promoter suggestsWolbachia inhibits early replication
events
AsWolbachia inhibits viral infection or subsequent processes as early as 7 hpi it could be
hypothesised that entry of the virus into cells is inhibited, leading to a significant reduction in
the number of subsequent replication complexes. In order to test this hypothesis we bypassed
viral entry and analysed early translation and replication by transfection of in vitro transcribed
capped SFV1(3F)RLuc-SG-FFLuc replicon RNA (Fig 1B). In this SFV-derived replicon RNA,
an open reading frame (ORF1) encoding RLuc is fused to the non-structural nsP3 and the sec-
ond, structural ORF(2) has been deleted and replaced with the FFLuc ORF (see Materials and
Methods). Alphavirus gene expression occurs in separate phases which are linked to replicative
processes. Initially ORF1 is translated from the RNA genome giving rise to the nsP proteins,
which carry out replicative functions. Then a switch from translation to replication occurs
leading to production of a full length antisense copy of the genome, the antigenome. Antisense
RNA (which most likely exists in a duplex with the original positive-strand genome) is used as
a template for synthesis of new genomes; in addition it carries an internal promoter sequence
that directs transcription of a subgenomic mRNA encoding the structural proteins (Fig 1) [39].
Thus, expression of structural proteins (or FFLucmarker, Fig 1B) takes place only from these
subgenomic RNAs i.e. is fully dependent on the replication process. In contrast, RLuc can be
produced both by directly translating the replicon that was transfected into the cells as well as
by translating new full-length positive strands, generated during RNA replication. Further-
more, in the absence of structural proteins no new virus particles can be formed preventing the
spread of infection. It was found thatWolbachia results in a significant inhibition of early
translation and/or replication independent of normal viral entry, with both RLuc and FFLuc
readouts being significantly lower in Jw18Wol cells compared to Jw18Free cells (Fig 3A and
3B). We cannot rule out thatWolbachiamay also have an effect on entry which we do not
observe in these assays.
As this SFV-derived replicon allows for the separate analysis of transcription and translation
from both the genomic and subgenomic promoters and corresponding mRNAs, it allows us to
further pinpoint the stage in the replication cycle that is affected byWolbachia. In theWolba-
chia infected cells we observed a 200–600 fold decrease in FFLuc readout, a marker expressed
from the RNA produced from subgenomic promoter, which is significantly greater (T-Test
P<0.0001) than the ~ 8 fold decrease in RLuc readout, a marker produced both from trans-
fected RNAs and full-length positive-strand transcripts from the genomic promoter. This
would suggest a clear and early inhibition of establishment of RNA replication. Alternatively, it
could indicate a specific defect in the production of the subgenomic mRNA. This could occur
either byWolbachia directly interfering with replication, or by preventing the translation of
proteins required for replication to occur and/or inhibiting the switch from replicase protein
translation to RNA replication. Overall the results indicate that early viral RNA translation
and/or replication were likely to be inhibited byWolbachia.
To further investigate the effect ofWolbachia on viral translation and/or replication we
uncoupled viral replicase proteins from viral RNA by the introduction of two plasmids into
cells in a SFV transreplicase assay. In this system, one plasmid encodes the viral replicase pro-
teins and the second encodes an RNA template containing the untranslated regions of SFV
with either FFLuc downstream of the genomic/actin promoter or Gluc downstream of the sub-
genomic promoter. In both cases the expressed sequences are under the control of a Drosophila
Actin promoter. Upon expression the replicase proteins will bind the RNA template and repli-
cation of the reporter construct will take place. Expression of FFLuc is under both the control
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of the Actin promoter and the genomic promoter, therefore due to the high expression from
the Actin promoter it is difficult to determine active replication from the genomic reporter.
However active replication can be measured from the production of the Gluc reporter which is
solely under the control of the subgenomic promoter. This system therefore allowed us to
determine if production of replicase proteins from mRNA transcribed in the nucleus could
overcomeWolbachia-mediated protection and determine if the origin of viral RNA is also
important. In order to rule out arbitrary effects we also generated a non-replicating replicase
with the introduction of a GDD-GAAmutation in the nsP4 protein, thus producing an inactive
replicase. Results are shown in Fig 3C and 3D. Activity from the Actin and SFV genomic pro-
moters appeared to be unaffected by the presence ofWolbachia, however it should be noted
Fig 3. The effect ofWolbachia on SFV replicon and transreplicase activity. (A, B) Jw18Wol and Jw18Free cells were transfected with in vitro transcribed
SFV1(3F)RLuc-SG-FFLucRNA, and both RLuc (A) and FFLuc (B) activity was measured 24 h post transfection (hpt). Graphs indicate mean fold change of
measurements of luciferase activity where activity in Jw18Wol cells is taken as 1 and represent three independent experiments carried out in triplicate. RLuc
activity represents translation of genome RNAs whereas FFLuc indicates translation of the subgenomic mRNA. Error bars represent standard error of mean.
Stars indicate significance where P = <0.05 in T-Test analysis. (C, D) Jw18Wol and Jw18Free cells were transfected with two plasmids: one expressing SFV
replicase proteins (wt or mutant, under the control of the D.melanogaster Actin promoter) and one expressing viral template and both FFluc (C) andGluc (D)
activity were measured 24 hpt. FFLuc activity represents translation of RNA produced from the Actin promoter (and to some extent the genomic promoter)
andGluc activity represents translation of RNA produced from the subgenomic promoter following replication. Graphs represent relative luciferase activity
and represent three independent experiments carried out in duplicate. Stars indicate significance where P = <0.01 in T-Test analysis.
doi:10.1371/journal.ppat.1005536.g003
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that there is no significant difference between the wildtype and mutant (GAA) replicase or cells
where no replicase-expressing plasmid had been transfected. This confirms that the activity we
saw here was most likely due to transcription from the Actin promoter and we are unlikely to
detect expression from the genomic promoter as the system is at an optimum (Fig 3C). This
has also been observed in mammalian systems [40]. As shown in Fig 3D, we observed thatWol-
bachia significantly lowered activity from the subgenomic promoter as Gluc activity is lower in
Jw18Wol cells compared to Jw18Free. This is in keeping with our previous observation that
Wolbachia is able to inhibit viral translation and/or replication. Once viral RNA template is
produced from the nucleus and transported to the cytoplasm, replication complexes are
thought to form as normal. ThusWolbachia was still able to confer protection even when viral
replicase/RNA delivery routes were changed. Taken together this data strongly indicated that
Wolbachia inhibits viral translation and/or replication.
Virus-derived siRNA profiles support an inhibitory effect ofWolbachia on
viral replicative processes
Amajor immune pathway in insects to fight viral infections is the exogenous siRNA pathway
which involves the production of virus-derived small interfering RNAs (viRNAs) by the
enzyme Dicer-2 acting on virus-derived dsRNA (such as viral replication intermediates) as a
substrate [26, 27, 41]. The hallmark of this pathway in insects is the production of 21 nucleo-
tide (nt) viRNAs, a process that has been described in detail for alphavirus infection of mosqui-
toes and mosquito cells [36, 37, 42]. To test whether the levels of viRNAs were affected by
Wolbachia we used high-throughput sequencing of 18-33nt small RNAs from Jw18 cells 24hpi
with SFV4(3H)-RLuc. In Jw18Free cells, small RNAs that were 21 nt long and map to the SFV
genome were strongly induced upon viral infection (Wilcoxon unpaired test: P = 0.008, Fig 4A,
S1A Fig for uninfected controls). 21 nt RNAs mapped equally in both sense and antisense ori-
entations to the viral genome (Fig 4A; P> 0.1 Chi-squared test against a uniform distribution).
The length and lack of strand bias or first nucleotide bias (Fig 4A) suggest that these small
RNAs are generated by the activity of Dicer-2 on virus-derived dsRNA, probably replication
intermediates; moreover 21 nt viRNAs were distributed across the viral genome as previously
reported for SFV (Fig 5A) [37, 43] and also other arboviruses [26, 27]. Indeed there was no
nucleotide bias seen at any position either in the Jw18Free or Jw18Wol cells (S2A and S2B Fig).
IfWolbachia infection were to reduce viral infection by upregulating antiviral RNAi we
would expect increased viRNA production in the presence ofWolbachia. However, whilst 21
nt viRNAs were still present above the background seen in virus-free controls (P = 0.008, Wil-
coxon unpaired test; Fig 4B and S1B Fig), the amount of viRNAs was strongly reduced on both
sense and antisense orientations relative toWolbachia-free cells (P = 0.008, Wilcoxon unpaired
test; Fig 4A versus 4B). Due to a significant reduction in viral replication, the distribution of 21
nt viRNAs from Jw18Wol cells revealed very few areas of viRNA production (Fig 5B and 5C).
RNAs smaller than 21 nt were similar between Jw18Wol and Jw18Free cells in infected cells
(Fig 4A and 4B), however it is likely that these smaller species of RNAs are background against
the D.melanogaster genome or degradation products.
This confirmed thatWolbachia does not protect against infection by enhancing the produc-
tion of small RNAs against viruses. Instead, these results are consistent with a model whereby
Wolbachia interferes with viral replication, leading to a decrease in the levels of viral replication
intermediates and therefore a reduction in dsRNA, the substrate available for Dicer-2 and
exogenous siRNA pathway induction. This is not surprising as previous studies have shown
thatWolbachia can still confer antiviral activity in flies mutant for key components of the
siRNA pathway [29].
Antiviral Protection byWolbachia
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Wolbachia does not alter the expression of miRNAs
Previous studies suggested thatWolbachia affects the sensitivity of mosquito cells to viral infec-
tion by altering host miRNAs levels [31, 32]. Therefore, we tested whetherWolbachia alters the
expression of known miRNAs in Jw18 cells. In the absence of virus, no miRNAs had signifi-
cantly different expression levels in Jw18Wol and Jw18Free cells (Fig 6 and S3A Fig). It is likely
therefore that any differences are not important toWolbachiamediated protection as in our
system there are no significantly altered miRNAs between non-infected Jw18Free and
Jw18Wol cells.
We next examined whetherWolbachia alters the miRNA response to viral infection. We
identified a number of miRNAs that significantly changed in abundance when Jw18Free cells
were infected with SFV (Figs 6 and S3D; S1 Table). Very similar changes in miRNA expression
were seen when cells withWolbachia were infected with virus (Fig 6 and S3B Fig, S1 Table).
However, when cells were infected with SFV there were no miRNAs whose abundance was
Fig 4. The effect ofWolbachia on the production of virus-derived small interfering RNAs in Jw18 cells. (A-B) The length and first nucleotide
distribution of small RNAs mapping to genome (upper bars, 50-30 orientation) or antigenome (lower bars, 3’-5’ orientation) of the SFV genome in the (A)
absence (Jw18Free) or (B) (Jw18Wol) presence ofWolbachia. A = red, C = green, G = blue and T = pink. Data are from 24 hpi with SFV4(3H)-RLuc, of Jw18
D.melanogaster cells. Concatenated data from 5 independent infections are shown in all panels.
doi:10.1371/journal.ppat.1005536.g004
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significantly changed by the presence ofWolbachia (Fig 6 and S3C Fig). Therefore in D.mela-
nogaster cells there is no evidence thatWolbachiamodulates the constitutive expression of
miRNAs or the miRNA-mediated response to infection. The similar miRNA response to virus
in cells with and withoutWolbachia is intriguing asWolbachia-infected cells have greatly
Fig 5. The effect ofWolbachia on the distrubution of virus-derived 21nt interfering RNAs in Jw18 cells.Distribution of 21 nt long viRNAs along sense
(upper bars, black; 5’-3’ orientation) or antisense (lower bars, red; 30-50 orientation) strands of the SFV genome in the absence (A) (Jw18Free) or presence
(B) (Jw18Wol) ofWolbachia. A zoomed in version of (B) is shown in (C) for ease of comparison. Data are from 24 hpi with SFV4(3H)-RLuc, of Jw18D.
melanogaster cells. Concatenated data from 5 independent infections are shown in all panels.
doi:10.1371/journal.ppat.1005536.g005
Antiviral Protection byWolbachia
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Fig 6. The effect ofWolbachia onD.melanogastermiRNA expression in the presence or absence of virus. Heatmap showing the effects ofWolbachia
and SFV4(3H)-RLuc virus on miRNA abundance. The mean of the No Virus-NoWolbachia treatment is set to zero. Only miRNAs that are significantly
(Adjusted p value<0.1, Negative Binomial Test) differentially expressed in at least one treatment are shown. Jw18Wol replicate WV 3 was included in
analysis; although it appeared to be an outlier as its inclusion did not alter the significance of the data. T = Jw18Free, W = Jw18Wol, V = SFV infection, O = no
SFV infection and numbers represent replicate.
doi:10.1371/journal.ppat.1005536.g006
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reduced levels of virus, and suggests it may reflect a sensitive response to initial infection by the
virus.
Absence of a transcriptional response ofWolbachia to viral infection
To investigate whetherWolbachia itself might mount an active antiviral response after infec-
tion, we tested if there is a transcriptional response ofWolbachia to viral infection. We
sequenced total RNA from Jw18Wol cells 7 and 24 hpi with SFV4(3H)-RLuc virus together
with uninfected controls. Over 229 million reads could be mapped to the D.melanogaster,Wol-
bachia or SFV transcriptomes (excluding D.melanogaster rRNA). Of these 85.6% mapped to
D.melanogaster and 12.4% mapped toWolbachia. In the virus-infected cells, 3.8% of reads
mapped to the SFV genome, and this dropped to 0.03% for cells that were not challenged with
the virus. NoWolbachia genes were differentially expressed in response to viral infection at
either time point (Fig 7B and 7C). There are three reasons to believe that this is a true lack of a
transcriptional response and not simply a lack of statistical power. First, across many tran-
scripts we were able to detect a transcriptional response of the cells to SFV in the same experi-
ment (Fig 7D and 7E), and the coverage of many of these differentially expressed transcripts
was lower than for manyWolbachia transcripts (Fig 7B–7E). Second, we had a very large data-
set. In each of the 4 treatments about two thirds of theWolbachia transcripts had over 100
reads mapped to them (Fig 7A), which is expected to give good power to detect differential
expression. Compared to most published RNAseq experiments ours was a highly replicated
experiment involving 40 libraries (biological replicates) across 4 lanes of Illumina HiSeq.
Third, if genes with very low-expression are ignored, our estimates ofWolbachia gene expres-
sion levels in cells with and without SFV were nearly identical (Fig 7B and 7C, log2FC0).
Therefore, the lack of differential expression cannot be attributed to a lack of statistical power.
Discussion
The bacterial symbiontWolbachia offers an exciting opportunity in the fight against arbovirus
transmission by mosquitoes. Several studies have found that it has antiviral activity in key arbo-
virus mosquito vectors [8, 28, 44, 45]. However, the exact mechanisms behind this activity are
poorly understood. In order forWolbachia to be used as a long term and sustainable system to
control arbovirus spread, it is critical that we understand these mechanisms. By combining two
powerful model systems–the model arbovirus SFV, and aWolbachia-infected D.melanogaster
cell line–we were able to show thatWolbachiamay protect against virus at a very early stage of
infection and appeared to block replication and/or translation of viral RNA. This did not
involve an active transcriptional response from either the host, the small RNA pathways or
Wolbachia itself.
Little is known about howWolbachia affects viral replication and dynamics, with studies
measuring changes in either the survival of infected insects or viral copy number [5, 6, 17–19].
To investigate the phenomenon in more depth we used the alphavirus SFV, for which virus-
encoded reporter genes are known to correspond well to viral replication [38]. We found that
Wolbachia is able to inhibit viral replication as early as 7 hpi. To our knowledge this is the first
indication thatWolbachia inhibits viral replication at such an early stage (for example by inhi-
bition of initial translation of incoming RNA or other early replicative processes), as previous
studies have focused mainly on days post-infection [5, 17, 19, 46]. This suggests that the mech-
anism by whichWolbachia is conferring antiviral activity is either fast acting or is already pres-
ent upon viral infection i.e. intrinsic. This is important as forWolbachia to be used successfully
as a control mechanism for arbovirus transmission, control of viral replicative processes at an
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early stage could be vital, as it would not allow the virus to replicate to high levels allowing for
dissemination.
The SFV life cycle can be divided into entry, initial translation of incoming viral genomes,
switch from translation to replication, RNA replication, translation of structural proteins from
subgenomic RNA, assembly and exit from cells. Understanding where in this lifecycleWolba-
chia acts is vital to understanding the mechanisms behind its antiviral activity. This can often
prove difficult to investigate as little is understood about SFV (and arbovirus) replication in
insect cells compared to vertebrate cells. By utilising SFV reporter viruses and replicon con-
structs we can begin to deconstruct the replication cycle. The very early stage at which SFV was
inhibited and the fact that bypassing viral entry still resulted in viral inhibition byWolbachia
suggests thatWolbachia is likely blocking an early post-entry stage in the replication cycle. We
can further dissect howWolbachia affects the replication cycle due to the presence of a sub-
Fig 7. Analysis of changes inWolbachia andD.melanogaster gene expression upon viral infection. Jw18Wol cells infected with SFV4(3H)-RLuc
were analyzed. (A) Sequence coverage ofWolbachia genes. Genes are arranged from lowest to highest coverage on the X axis. In the legend + refers to the
presence of SFV. (B-C) The response to infection (log2 fold expression change) for eachWolbachia gene is shown against expression level (average log2
count per million [CPM]) at (B) 7 h and (C) 24 h after infection. (D-E) The response to infection of D.melanogaster genes. Genes that significantly change in
expression at 10% false discovery rate (FDR) are shown in red (there were no significant induction/repression forWolbachia genes).
doi:10.1371/journal.ppat.1005536.g007
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genomic promoter in alphaviruses [39, 47]. Expression from the first ORF of SFV does not
require viral replication (though due to an increase of genomic RNA copy number, it is dra-
matically increased when replication occurs), as positive-sense RNA virus genomes can act as
mRNA immediately after infection. In contrast translation and protein expression from the
second ORF of SFV requires a full round of replication in order for the sub-genomic promoter
to become available. Therefore by utilising the replicon SFV expressing RLuc reporter directly
from genomic RNA and FFLuc via activity of the subgenomic promoter we could test whether
Wolbachia is affecting the replication of viral RNA. Our results showed that viral replication
and/or translation of replicon were inhibited byWolbachia. This could occur either byWolba-
chia directly interfering with replication, or by inhibiting the translation of viral proteins
required for this to occur and/or inhibiting the switch from translation to replication. Further
to this we showed by using a SFV transreplicase system and uncoupling the replicase proteins
from template RNA that there was significant inhibition of the subgenomic promoter and thus
viral translation and/or replication. Thus providing replicase proteins either directly or sepa-
rately did not overcome the inhibition phenotype. These results indicate that the origin of viral
RNA (transcription in the nucleus in the transreplicase system) was also not important toWol-
bachia-mediated antiviral activity.
This block in translation/replication in the presence of the endosymbiont was backed by
analysis of the induction of small RNA responses, which reveal thatWolbachia-infected cells
did not show higher production of viRNAs which are derived from the dsRNA generated dur-
ing viral replication (see below).
One possible way in whichWolbachia could protect against viruses would be by the bacte-
rium mounting an active antiviral response following infection. If this were the case, it would
likely be reflected in a transcriptional response of the endosymbiont to the virus. However, in a
very large dataset we did not find a singleWolbachia gene that was differentially regulated in
response to viral infection. This is consistent with the very early inhibition of viral replication,
which suggests that the antiviral mechanism is constitutively present before the virus infects
the cell and is thus intrinsic.
Previous studies have indicated that a host miRNA response may be responsible forWolba-
chia’s antiviral activity [30, 31, 48], but we found no support for this hypothesis in our system.
In virus-free mosquitoesWolbachia changes the expression of a number of miRNAs, but we
found no such differences in our cell line (S3E Fig). Previous studies did not analyze concurrent
infections of bothWolbachia and virus [30, 31, 48]. When we did this we found a marked
miRNA response to the virus, but this was unaltered by the presence ofWolbachia. It is surpris-
ing that we still see host miRNA response to viral infection in the presence ofWolbachia, as the
level of SFV infection is extremely low. This suggests that miRNA response may be due to early
events in viral replication such as virion binding and/or entry or that this response requires
very little viral protein synthesis/RNA replication to be initiated. Previous studies have indi-
cated that the viRNA pathway is not required forWolbachia’s antiviral activity [29]. Our data
supports this, with a strong reduction in 21 nt viRNAs mapping to the SFV genome and antige-
nome whenWolbachia is present. This suggests that viral replication is inhibited so signifi-
cantly that very few viRNAs are produced, rather thanWolbachia inducing an antiviral RNAi
response. Further studies utilising this system would be beneficial to the field. For example little
is known about the possibility of viruses mutating to overcomeWolbachiamediated protection
as long term studies are lacking. A cell-based assay offers an ideal opportunity to look at virus
evolution over the long term in such associations. In addition to this it would be interesting to
look at the effect on other viruses in our system as other studies have indicated that even within
the same familyWolbachia can have different effects on viruses [49]. In Drosophila studies
Wolbachia is also known to protect against FHV without lowering viral titres. It would be
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interesting to look at this in the context of our findings, as it may suggest another mechanism
by whichWolbachia can confer antiviral activity [6].
In conclusion we have developed a powerful new system to study the replication dynamics
of SFV inWolbachia-infected D.melanogaster cells. While the exact mechanism of the antiviral
response remains unknown, current data is consistent with a ‘passive’mechanism such as com-
petition for resources or space, or byWolbachia remodelling the intracellular environment.
While effects ofWolbachia on entry or exit cannot be excluded, our data point to an effect on
translation and/or replication at least for this model alphavirus. Considering the broad antiviral
effects ofWolbachia across Drosophila and mosquito species, it is tempting to propose a model
of inhibition that relies on similar intrinsic mechanisms rather than diverse processes such as
miRNA regulation or immune responses. The data presented in this study point towards such
an antiviral mode of action byWolbachia endosymbionts.
Materials and Methods
Cell culture
TheWolbachia-infected D.melanogaster cell line Jw18Wol (obtained fromW. Sullivan, L. Ser-
bus, A. Debec) has been described elsewhere [34]. A corresponding tetracycline cured line
(Jw18Free) was created by treating cells with 10 μg/ml of tetracycline for 4 passages, cells were
then tested forWolbachia by PCR and DAPI staining and if the infection was cleared cells were
left for 5 more passages in order to eliminate tetracycline effects. Cells were maintained at 24°C
in Shields and Sanger media (Sigma) supplemented with 10% fetal calf serum (FCS) and 10%
Penicillin/Streptomycin (Pen/Strep). Cells were checked every four passages for the presence of
Wolbachia by PCR using two separate primer pairs as described previously [6]; cells were
stained with DAPI in order to visualiseWolbachia content (shown as dots in cytoplasm), den-
sity in Jw18Wol cells was consistent with previous observations with ~90% of cells infected (S4
Fig). qPCR was also carried out in order to determineWolbachia density. Standard curve anal-
ysis was carried out and normalised to an Actin endogenous control. Primers used were as fol-
lows, Actin5CF_ GACGAAGAAGTTGCTGCTCTGGTTG Actin5CR TGAGGATACCA
CGCTTGCTCTGC and WolF GTTTGCAATACAACGGTGAAWolR CAACCCTGA
TGTCGTCCATT. qPCR was carried out using the ABI Fast SYBR Green Master Mix, as per
manufactures guidelines, on an ABI 750 Fast machine. Results indicated that when compared
to Actin endogenous control there is ~22 times moreWolbachia (S5 Fig), suggesting a density
of at least 100% with more than one copy number per cell as is seen in the DAPi staining.
Virus production and in vitro transcription of replicon RNA
SFV4(3H)-RLuc virus was grown and cultivated as described previously [37]. For replicon pro-
duction, pSFV1(3F)RLuc-SG-FFLuc plasmid (details available on request) was linearized with
SpeI and purified using the PCR product purification kit (Roche). 1 μg of linearized DNA was
in vitro transcribed using MEGAscript SP6 polymerase kit (Ambion) in the presence of cap
analog (Ambion).
SFV transreplicase system: construction of replicase and template
expression constructs
pAc51-V5-His backbone was used to construct the plasmid expressing the replicase of SFV.
First, the multiple coning site of the plasmid was replaced by a polylinker sequence TTCGAA
TATGGATCCTATTTAATTAATATCCTAGG (recognition sites of Bsp119I and PacI are
underlined). Second, Bsp119I and PacI adapters were added to the 5’ and 3’ ends of the
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sequence encoding SFV replicase, respectively, by using PCR and subcloning procedures.
Finally, the sequence encoding SFV replicase was inserted into modified pAc51 vector using
Bsp119I and PacI restriction sites. The resulting plasmid was designated as pAct51-SFVRepl.
In order to obtain plasmid encoding for a polymerase defective form of SFV replicase, the con-
served GDD motif in nsP4 was altered to GAA using PCR-based mutagenesis and subcloning
procedures; the resulting plasmid was designated pAc51-SFVRepl-GAA.
In order to obtain a plasmid for expression of template RNA for the SFV replicase the poly-
linker and terminator regions of pAc51-V5-His were replaced with a synthetic DNA fragment
consisting from the first 280 nucleotides of SFV genome (including EcoRV restriction site,
nucleotides 275–280) followed by the sequence TATGGATCCTATGGCGCGCCGTCGAC
(recognition sites BamHI, BssH2 and SalI underlined). The replacement was performed in
such a way that the 5’ end of the SFV genome was positioned exactly downstream of last start
site of actin promoter. The following sequences were added using synthetic DNA fragments
(GenScript, USA) and subcloning procedures: a) sequence encoding for firefly luciferase
(FFLuc), placed in frame with N-terminal fragment of SFV nsP1 (amino acid residues 1–65,
encoded by the 5’ region of SFV genome); b) SFV subgenomic promoter spanning from posi-
tion -145 to +51 with respect of the start site of SFV subgenomic RNA; c) sequence encoding
for Gaussia luciferase (Gluc); d) 3’UTR of SFV followed by 69 adenine residues; e) negative
strand ribozyme of hepatitis delta virus; e) late termination region of simian virus 40. Elements
a, b, c and d were separated from each other by recognition sequences of EcoRV, ApaI and
Bsp119I nucleases, respectively. The plasmid was designated as pAc51-Temp-Fluc2-SG-Gluc.
Infection of cells with SFV
Cells were plated out at a density of 3.5x105 cells/well 24 h prior to infection in a 24 well plate.
For infection, virus was diluted in Shields and Sanger media (Sigma) with no FCS. Virus was
titred as described [37] and an MOI of 20 was shown to give an infectivity of over 90% in
Jw18Free cells (S4C Fig). Cells were incubated for 3 h before media was replaced with fresh
media supplemented with 10% FCS and Pen/Strep. Samples were collected at time points as
indicated. Virus free cells were mock infected by treating the same as infected cells but without
the addition of virus to the media.
Immunofluorescence detection ofWolbachia and SFV
Wolbachia was detected using the nuclear stain DAPI. Briefly cells were fixed in 4% parafor-
maldehyde, permeabilized and covered in Vectashield containing DAPI.Wolbachia was indi-
cated by the presence staining outside of the nucleus which was absent in tetracycline treated
cells. SFV was detected as described previously using an antibody against the replicative protein
nsP2 [50].
Transfection of cells with SFV1(3F)RLuc-SG-FFLuc replicon RNA or
SFV transreplicase plasmids
Cells were plated out at a density of 3.5x105 cells/well 24 h prior to transfection in a 24 well
plate. Cells were transfected with 1 μl of in vitro transcribed RNA using Fugene in Shields and
Sanger media minus FCS. Cells were incubated for 2 h before media was replaced with fresh
media supplemented with 10% FCS and Pen/Strep. For transreplicase experiments 300 ng of
each plasmid was transfected into cells as described above.
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Luciferase assays
Cells were lysed in passive lysis buffer and luciferase readings carried out using the Dual Lucif-
erase Kit (Promega). Luciferase activities were determined on a Glomax Multi+ Microplate
Multimode reader (Promega).
Sequencing and analysis of small RNAs
Cells were infected with SFV as described above. At 7 and 24 hpi cells were lysed in 1 ml of Tri-
zol solution. Small RNA libraries were prepared according to the Illumina method using the
Truseq small RNA Preparation kit. We made a small adjustment to the manufacturer’s proto-
col to include a ribosomal RNA blocking step prior to ligation of 5´ adapter and reverse tran-
scription in order to eliminate the abundant 30 nt D.melanogaster 2S rRNA, as specified in
[51]. Small RNA libraries were then sequenced on one lane of a HiSeq 2000. High throughput
sequencing data was processed and aligned to the viral genome as described previously [52].
miRNAs were mapped to D.melanogastermiRNAs downloaded from miRBase [53] using a
custom Perl script and analysed to identify statistically significant changes in expression
according to the negative binomial distribution using the R package DESeq as described [54].
All data processing was carried out in the R statistical environment. Sequence data has been
submitted to the Sequence Read Archive (SRA) under accession number PRJEB9710.
Sequencing and analysis of total RNA
Wolbachia-positive Jw18Wol cells were infected with SFV at an MOI of 20 as described above. 7
and 24 hpi cells were lysed in 1 ml of Trizol; total RNA was extracted using the Direct-Zol Mini-
Prep kit (Zymo). The extracted RNA was then treated with TURBODNase (Ambion) and puri-
fied using the RNA Clean and Concentrator kit (Zymo).D.melanogaster ribosomal RNA was
then depleted using the Ribo-Zero Gold Magnetic kit (Human/Mouse/Rat, Epicentre). Libraries
of the rRNA-depleted total RNA were prepared at The Genome Analysis Center (Norwich) with
the Truseq RNA Sample Preparation kit (Illumina) and sequenced in 2 lanes on a HiSeq 2000.
Sequence data has been submitted to the Sequence Read Archive (SRA) under accession number
PRJEB10681. Sequences were quality trimmed from the 5´ and 3´ ends using Trimmomatic ver-
sion 0.30 [55] when average quality scores in sliding windows of 4 base pairs dropped below 20
or when the quality score at the beginning or end of the read dropped below 20. Sequences less
than 25 bp in length were discarded. Reads were aligned to the transcriptomes ofWolbachia
strain wMel (Genbank accession number: GCA_000008025.1) and D.melanogaster (BDGP v.
5.25), and to the genome of SFV (Genbank: KP699763.1). Alignments were performed using
Bowtie2 version 2.1.0 [56] with default parameters, and splicing was allowed inD.melanogaster
using TopHat2 version 2.0.9 [57] with default parameters and no novel junctions allowed. The
numbers of reads per transcript were counted using HTSeq [58] forWolbachia andD.melanoga-
ster. Differential expression analysis was performed using edgeR [59]. Lowly expressed genes
were filtered out by requiring that each gene have at least 1 count per million in at least 8 samples.
Differential expression in response to viral infection was measured separately at 7 and 24 hpi. Sig-
nificance was assessed using exact tests [59] with a FDR of 10%.
Supporting Information
S1 Fig. Analysis of small RNAs profiles in virus-free cells in the different treatments. This
data is the virus-free controls for Fig 4A and 4B in the main text. The length and first nucleotide
distribution of small RNAs mapping to SFV genome (upper bars, 50-30 orientation) or antigenome
(lower bars, 3’-5’ orientation) at 24 h post mock infection ofD.melanogaster cells in the absence
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(A) (Jw18Free) or presence (B) (Jw18Wol) ofWolbachia are shown. Concatenated data from 5
independent infections are shown. A = red, C = green, G = blue and T = pink.
(TIF)
S2 Fig. The effect ofWolbachia on the distribution of nucleotides in virus-derived small
interfering RNAs (viRNAs).Mapping of nucleotide distribution of small RNAs mapping to
the SFV genome in the (A) (Jw18Free) absence or (B) (Jw18Wol) presence ofWolbachia.
A = red, C = green, G = blue and T = pink.
(TIF)
S3 Fig. The expression of miRNAs inD.melanogaster Jw18 cells with (Jw18Wol) and with-
out (Jw18Free)Wolbachia, and with and without virus (SFV) infection. Panels (A-D) are
volcano plots summarizing the differential expression of miRNAs between pairs of treatments.
The Y axis is the log10 of the FDR corrected P value. The X axis is the change in expression on a
log2 scale. (E) Heatmap showing the relative expression of miRNAs homologous to those
reported to be affected byWolbachia infection of mosquito cells [48]. T = Jw18Free,
W = Jw18Wol, V = SFV infection, O = no SFV infection and numbers represent replicate.
(TIF)
S4 Fig. Detection ofWolbachia infection by DAPI staining. Cells were tetracycline treated
or not and stained with DAPI in order to visualizeWolbachia infection; tetracycline-treated
cells are referred to as Jw18Free. (A) Cells were checked for the presence ofWolbachia by PCR
using two separate primer pairs as described previously [6]. (B) Cells were then stained with
DAPI in order to visualiseWolbachia content, density was consistent with previous observa-
tions with ~90% of cells infected. (C) Jw18Free cells were infected with an MOI of 20 calculated
in BHK cells and stained with SFV NSP2 antibody [50] in order to determine infection rate.
Cells positive for SFV were shown to have an infection rate>90%.
(TIF)
S5 Fig. Calculation ofWolbachia density by qPCR.Wolbachia density was calculated as a
ratio to the endogenous control Actin 5C (Wol/Act), where it is assumed there is one copy of
actin per cell. Experiments were carried out in triplicate with two biological replicates. Error
bar indicates standard deviation.
(TIF)
S1 Table. List of miRNAs significantly differentially expressed in response to SFV in cells
both with and withoutWolbachia. Table indicates miRNAs found to be significantly differen-
tially expressed (Adjusted p value<0.1, Negative Binomial Test) upon SFV infection in either
cells positive (Jw18Wol) or negative (Jw18Free) forWolbachia. Black means significantly upre-
gulated and red significantly down regulated.
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